Total Payments
$3,537
2024 Payments
$369.66
Companies
40
Transactions
149
Medicare Patients
27,861
Medicare Billing
$6.6M
Payment Breakdown by Category
Food & Beverage$2,619 (74.0%)
Research$461.85 (13.1%)
Consulting$444.89 (12.6%)
Education$11.92 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,619 | 146 | 74.0% |
| Unspecified | $461.85 | 1 | 13.1% |
| Consulting Fee | $444.89 | 1 | 12.6% |
| Education | $11.92 | 1 | 0.3% |
Payments by Type
General
$3,075
148 transactions
Research
$461.85
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $461.85 | 1 | $0 (2021) |
| McKesson Specialty Care Distribution Corp. | $444.89 | 1 | $0 (2017) |
| Janssen Biotech, Inc. | $396.09 | 25 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $286.56 | 15 | $0 (2023) |
| ABBVIE INC. | $225.79 | 10 | $0 (2024) |
| Pharmacyclics LLC, an AbbVie Company | $212.51 | 11 | $0 (2022) |
| Sirtex Medical Inc | $138.43 | 2 | $0 (2019) |
| PFIZER INC. | $132.51 | 11 | $0 (2021) |
| Amgen Inc. | $116.76 | 8 | $0 (2022) |
| Merck Sharp & Dohme LLC | $100.40 | 6 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $369.66 | 18 | ABBVIE INC. ($54.76) |
| 2023 | $402.74 | 18 | AbbVie Inc. ($146.83) |
| 2022 | $508.62 | 28 | Janssen Biotech, Inc. ($103.28) |
| 2021 | $956.80 | 31 | Eli Lilly and Company ($461.85) |
| 2020 | $97.15 | 5 | Novartis Pharmaceuticals Corporation ($47.25) |
| 2019 | $308.46 | 13 | Sirtex Medical Inc ($128.00) |
| 2018 | $203.51 | 15 | PFIZER INC. ($49.51) |
| 2017 | $690.23 | 21 | McKesson Specialty Care Distribution Corp. ($444.89) |
All Payment Transactions
149 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/20/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $19.74 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/08/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $32.40 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Janssen Biotech, Inc. | TALVEY (Biological) | Food and Beverage | In-kind items and services | $19.26 | General |
| Category: Oncology | ||||||
| 11/06/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $21.23 | General |
| Category: ONCOLOGY | ||||||
| 10/21/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $20.94 | General |
| Category: Oncology | ||||||
| 09/25/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $20.51 | General |
| Category: Oncology | ||||||
| 09/05/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $16.70 | General |
| Category: ONCOLOGY | ||||||
| 07/18/2024 | Janssen Biotech, Inc. | TALVEY (Biological) | Food and Beverage | In-kind items and services | $19.27 | General |
| Category: Oncology | ||||||
| 06/26/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $23.74 | General |
| 06/20/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $14.26 | General |
| Category: Oncology | ||||||
| 06/19/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $19.46 | General |
| Category: Oncology | ||||||
| 06/04/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $32.91 | General |
| Category: Oncology | ||||||
| 06/03/2024 | RECORDATI_RARE_DISEASES_INC. | SYLVANT (Drug) | Food and Beverage | In-kind items and services | $19.88 | General |
| Category: ONCOLOGIC AGENT | ||||||
| 05/14/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $13.89 | General |
| Category: ONCOLOGY | ||||||
| 05/02/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $21.92 | General |
| Category: ONCOLOGY | ||||||
| 04/09/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $13.28 | General |
| Category: ONCOLOGY | ||||||
| 03/27/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $16.14 | General |
| Category: ONCOLOGY | ||||||
| 02/05/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $24.13 | General |
| Category: Hematology | ||||||
| 12/23/2023 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $31.86 | General |
| Category: ONCOLOGY | ||||||
| 12/01/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $31.50 | General |
| Category: ONCOLOGY | ||||||
| 10/03/2023 | Daiichi Sankyo Inc. | — | Food and Beverage | In-kind items and services | $25.64 | General |
| 09/20/2023 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $19.18 | General |
| Category: Oncology | ||||||
| 09/07/2023 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $16.10 | General |
| Category: Oncology | ||||||
| 07/10/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $23.87 | General |
| Category: ONCOLOGY | ||||||
| 07/06/2023 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $19.16 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY | Eli Lilly and Company | $461.85 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 73 | 5,785 | 126,207 | $7.6M | $1.6M |
| 2022 | 79 | 6,927 | 107,038 | $4.7M | $918,395 |
| 2021 | 87 | 8,176 | 151,260 | $10.5M | $2.1M |
| 2020 | 67 | 6,973 | 118,547 | $9.1M | $1.9M |
Total Patients
27,861
Total Services
503,052
Medicare Billing
$6.6M
Procedure Codes
306
All Medicare Procedures & Services
306 procedure records from CMS Medicare Utilization — Page 1 of 13
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 15 | 15,200 | $2.6M | $621,933 | 23.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 90 | 15,480 | $1.2M | $271,378 | 23.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 605 | 2,176 | $909,329 | $189,751 | 20.9% |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2023 | 27 | 21,105 | $652,365 | $158,966 | 24.4% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 31 | 3,200 | $254,400 | $48,303 | 19.0% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 27 | 6,950 | $290,719 | $38,693 | 13.3% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 25 | 104 | $219,939 | $33,346 | 15.2% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 12 | 360 | $229,360 | $32,092 | 14.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 70 | 309 | $181,961 | $27,438 | 15.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 111 | 111 | $78,738 | $16,407 | 20.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 569 | 1,808 | $22,701 | $15,179 | 66.9% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 42 | 39,270 | $137,445 | $14,747 | 10.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 521 | 1,873 | $71,867 | $14,246 | 19.8% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 60 | 491 | $116,347 | $9,863 | 8.5% |
| 88185 | Flow cytometry technique for dna or cell analysis, each additional marker | Office | 2023 | 22 | 552 | $76,651 | $8,900 | 11.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 196 | 910 | $70,807 | $8,832 | 12.5% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 358 | 785 | $52,038 | $8,125 | 15.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 46 | 52 | $25,717 | $6,563 | 25.5% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 53 | 70 | $27,019 | $6,313 | 23.4% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 33 | 35 | $39,316 | $5,530 | 14.1% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 24 | 114 | $28,947 | $5,070 | 17.5% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2023 | 360 | 833 | $24,832 | $4,931 | 19.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 65 | 93 | $26,899 | $3,989 | 14.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 30 | 31 | $21,876 | $3,805 | 17.4% |
| 80047 | Blood test, basic group of blood chemicals (calcium, ionized) | Office | 2023 | 103 | 280 | $13,457 | $3,769 | 28.0% |
About Dr. Cynthia Shepherd, MD
Dr. Cynthia Shepherd, MD is a Hematology & Oncology healthcare provider based in Athens, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/04/2007. The National Provider Identifier (NPI) number assigned to this provider is 1730236688.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Cynthia Shepherd, MD has received a total of $3,537 in payments from pharmaceutical and medical device companies, with $369.66 received in 2024. These payments were reported across 149 transactions from 40 companies. The most common payment nature is "Food and Beverage" ($2,619).
As a Medicare-enrolled provider, Shepherd has provided services to 27,861 Medicare beneficiaries, totaling 503,052 services with total Medicare billing of $6.6M. Data is available for 4 years (2020–2023), covering 306 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Athens, GA
- Active Since 01/04/2007
- Last Updated 07/19/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1730236688
Products in Payments
- IMBRUVICA (Drug) $255.03
- VENCLEXTA (Drug) $192.95
- MEKINIST (Drug) $162.12
- DARZALEX (Biological) $159.14
- SIR-Spheres Microspheres (Device) $138.43
- XTANDI (Drug) $110.01
- KEYTRUDA (Biological) $100.40
- ERLEADA (Drug) $99.96
- Enhertu (Drug) $74.27
- Nplate (Biological) $62.83
- IBRANCE (Drug) $59.12
- GAZYVA (Biological) $55.08
- KISQALI (Drug) $52.65
- ALOXI (Drug) $48.37
- SARCLISA (Biological) $39.97
- Nerlynx (Drug) $39.14
- TALVEY (Biological) $38.53
- ZYTIGA (Drug) $36.42
- OPDUALAG (Drug) $35.20
- Orserdu (Drug) $32.91
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Athens
Dr. Priya Rudolph, Md, Phd, MD, PHD
Hematology & Oncology — Payments: $666,297
Hematology & Oncology $666,297
Amanda Hathaway, M.d, M.D
Hematology & Oncology — Payments: $147,716
Hematology & Oncology $147,716
Dr. Charles Bodine, M.d, M.D
Hematology & Oncology — Payments: $9,979
Hematology & Oncology $9,979
Dr. Frederick Flynt, M.d, M.D
Hematology & Oncology — Payments: $9,466
Hematology & Oncology $9,466
Shawn Tai, M.d, M.D
Hematology & Oncology — Payments: $9,190
Hematology & Oncology $9,190
Ms. Addie Hill, M.d, M.D
Hematology & Oncology — Payments: $5,608
Hematology & Oncology $5,608